Procarta’s novel pipeline and DNA-based compounds have the potential to revolutionise the treatment of serious and life-threatening infection, including those caused by multiple drug resistant pathogens.
In order to build and progress Procarta’s pipeline we are pursuing a collaborative approach. As such, we welcome strategic partnering opportunities in our antimicrobial programmes with a focus on;
- Enterobacteriaceae / CRE
- Streptococcus / Staphylococcus / MRSA
- Clostridium difficile
- Respiratory pathogens
- Platform capability for specific bacterial species or populations
In order to expand R&D capabilities and our pipeline, we also welcome partnership in Microbiota engineering to provide opportunities to advance the field of precision medicine.